<DOC>
	<DOCNO>NCT02622763</DOCNO>
	<brief_summary>Intralesional Tolerogenic Dendritic Cells Crohn 's Disease Treatment .</brief_summary>
	<brief_title>Intralesional Tolerogenic Dendritic Cells Crohn 's Disease Treatment</brief_title>
	<detailed_description>The main objective evaluate safety clinical response intralesional injection Autologous peripheral blood differentiate adult dendritic cell expand tolerogenic patient refractory Crohn 's disease treatment .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Confirmed diagnosis Crohn 's disease ( Lennard Jones criterion ) 2 . Active Crohn 's disease last six month inclusion define : CDAI ? 220 endoscopic radiological criterion activity 3 . Refractory intolerance conventional therapy include corticosteroid , immunomodulators antitumor necrosis factoralpha 4 . Presence visible lesion endoscopy 5 . Acceptance participate study write informed consent 1 . No injury prescreening resonance 2 . Pregnancy , lactation woman childbearing age take appropriate contraceptive measure 3 . Patients HIV + Hepatitis C Virus + Hepatitis B Virus + 4 . Serious concomitant disease : Renal failure creatinine clearance &lt; 40ml / min Heart disease : congestive heart failure ejection fraction &lt; 45 % , atrial fibrillation treat oral anticoagulant , uncontrolled ventricular arrhythmia , pericarditis , pleural effusion hemodynamic Neoplasms myelodysplasia Psychiatric disorder include alcohol drug 5 . Symptoms attributable fibrotic stricture Crohn 's disease discretion investigator 6 . Diarrhea attributable `` short bowel syndrome '' 7 . Active infection , include tuberculosis 8 . Participation research study new drug 3 month prior inclusion . 9 . Vaccination live/attenuated germ previous 3 month 10 . Personal history cancer ( active complete remission ) know family history hereditary cancer . 11 . Patients , observation state vein , consider inaccessible impossible perform apheresis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Tolerogenic Dendritic Cells</keyword>
</DOC>